Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EPAM Systems Inc (EPAM) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance

EPAM Systems IncTrade
Vaxcyte Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

EPAM Systems Inc vs Vaxcyte Inc. Common Stock — how do they compare? EPAM Systems Inc trades at $115.12 (market cap $5.96B), while Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is the larger of the two by market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and Vaxcyte Inc. Common Stock for 0 Days on average.

EPAMPCVX
Market Cap
$5.96B$10.51B
Volume
731,3692,644,694
Sector
TechnologyHealth
52-Week High
$221.40$73.82
52-Week Low
$76.04$40.32
Typical Hold Time
37 Days0 Days
Enterprise Value
$5.32B$9.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EPAM Systems Inc

EPAM Systems trades at $114.63, up 1.41% today, with a bullish technical signal and strong fundamental valuation metrics including a P/E of 15.67 and P/S of 1.12. Recent quarterly earnings have consistently beaten expectations, and the company announced a partnership with Wiz to enhance cloud security (PRNewsWire, 2026-08-25).

The outlook is positive with a consensus price target of $119, representing ~4% upside. Key opportunities include AI-native revenue growth exceeding 11% (Seeking Alpha, 2026-09-02), while risks involve slower North American growth and activist pressure for buybacks (Reuters, 2026-08-31).

Vaxcyte Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EPAM

No sentiment data available yet.

PCVX
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About EPAM Systems Inc

EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.

Read more on EPAM →

About Vaxcyte Inc. Common Stock

Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.

Read more on PCVX →